Lorecivivint
Lorecivivint is a small molecule pharmaceutical. It is currently being investigated in clinical studies. It is known to target dual specificity tyrosine-phosphorylation-regulated kinase 1A and dual specificity protein kinase CLK2.
Download report
Favorite
Commercial
Therapeutic Areas
No data
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
No data
Labels
FDA
EMA
No data
Indications
FDA
EMA
No data
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
No data
HCPCS
No data
Clinical
Clinical Trials
12 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
No data
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Knee osteoarthritis | D020370 | EFO_0004616 | M17 | — | 3 | 5 | — | — | 8 |
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Osteoarthritis | D010003 | EFO_0002506 | M15-M19 | 1 | 1 | — | — | — | 2 |
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Drug interactions | D004347 | 1 | — | — | — | — | 1 | ||
| Intervertebral disc degeneration | D055959 | HP_0008419 | 1 | — | — | — | — | 1 |
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | LORECIVIVINT |
| INN | lorecivivint |
| Description | Lorecivivint is a small molecule pharmaceutical. It is currently being investigated in clinical studies. It is known to target dual specificity tyrosine-phosphorylation-regulated kinase 1A and dual specificity protein kinase CLK2. |
| Classification | Small molecule |
| Drug class | vinca alkaloids; WNT (wingless-type mouse mammary tumor virus) pathway inhibitors |
| Image (chem structure or protein) | |
| Structure (InChI/SMILES or Protein Sequence) | CC(C)CC(=O)Nc1cncc(-c2ccc3[nH]nc(-c4nc5cncc(-c6cccc(F)c6)c5[nH]4)c3c2)c1 |
Identifiers
| PDB | — |
| CAS-ID | 1467093-03-3 |
| RxCUI | — |
| ChEMBL ID | CHEMBL4297639 |
| ChEBI ID | — |
| PubChem CID | — |
| DrugBank | — |
| UNII ID | 42EK42WHI5 (ChemIDplus, GSRS) |
Target
Agency Approved
No data
Alternate
DYRK1A
DYRK1A
CLK2
CLK2
Organism
Homo sapiens
Gene name
DYRK1A
Gene synonyms
DYRK, MNB, MNBH
NCBI Gene ID
Protein name
dual specificity tyrosine-phosphorylation-regulated kinase 1A
Protein synonyms
dual specificity tyrosine-(Y)-phosphorylation regulated kinase 1A, Dual specificity YAK1-related kinase, hMNB, HP86, mnb protein kinase homolog hp86, MNB/DYRK protein kinase, MNBH, Protein kinase minibrain homolog, serine/threonine kinase MNB, serine/threonine-specific protein kinase
Uniprot ID
Mouse ortholog
Dyrk1a (13548)
dual specificity tyrosine-phosphorylation-regulated kinase 1A (Q61214)
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 100 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
0 adverse events reported
View more details
Premium feature
Learn more about premium features at pharmakb.com
Learn more